ALFACELL CORP
424B3, 1996-11-06
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: FIDELITY MT VERNON STREET TRUST, 497, 1996-11-06
Next: PAR TECHNOLOGY CORP, 10-Q, 1996-11-06




                                                            *File No. 33-83072 
                                                             (also relating to
                                                             file nos. 33-76950
                                                             and 33-63341)
                                                            *File Pursuant to
                                                             Rule 424(b)(3)


                              ALFACELL CORPORATION


                                SUPPLEMENT NO. 1
                     TO PROSPECTUS DATED SEPTEMBER 13, 1996
          RELATING TO 3,767,787 SHARES OF COMMON STOCK, $.001 PAR VALUE

         The   Prospectus  is  hereby   supplemented   by  amending   "Executive
Compensation  - Summary  Compensation  Table" to reflect  the  extension  of the
exercise  period of the options  discussed  in  footnote  3, below,  so that the
Summary Compensation Table reads in its entirety as follows:


                           SUMMARY COMPENSATION TABLE

         The   following   table   provides  a  summary  of  cash  and  non-cash
compensation  for each of the last three fiscal years ended July 31, 1996,  1995
and 1994 with respect to  Alfacell's  Chief  Executive  Officer and the only two
other executive  officers of the Company during the last three fiscal years (the
"Named Executive Officers").

<TABLE>
<CAPTION>

                                                                                                   Long Term
                                                                                                 Compensation
                                                                                               ---------------
                                                     Annual Compensation
                                --------------------------------------------------------------
                                                                                                  Securities
                                                                                Other             Underlying
                                                                                Annual             Options/            All Other
           Name and                                                          Compensation           SARs(#)          Compensation
      Principal Position            Year      Salary($)      Bonus($)           ($)(1)         ---------------            ($)
- ----------------------------      -----     ----------     ---------      ----------------                         ---------------

<S>                                 <C>          <C>          <C>               <C>             <C>                     <C>
Kuslima Shogen                      1996         $150,000     - 0 -             - 0 -             500,000(3)            - 0 -
 Chief Executive Officer and        1995          150,000     - 0 -             - 0 -              - 0 - (4)            - 0 -
 Chairman of the Board of           1994          150,000     - 0 -             - 0 -           1,306,529(2)            - 0 -
 Directors(2)

Gail E. Fraser(5)                   1996         $130,000     - 0 -             - 0 -              - 0 -                - 0 -
 Vice President,                    1995          121,163     - 0 -             - 0 -              - 0 - (4)            - 0 -
 Finance and Chief                  1994            8,333     - 0 -             - 0 -             475,000(6)            - 0 -
 Financial Officer

Stanislaw M. Mikulski(7)            1996         $130,000     - 0 -             - 0 -             250,000(3)            - 0 -
 Executive Vice President           1995          130,000     - 0 -             - 0 -              - 0 - (4)            - 0 -
 and Medical Director               1994          130,000     - 0 -             - 0 -             431,409(7)            - 0 -



(1)      Excludes  perquisites  and other personal  benefits that in the
         aggregate do not exceed 10% of the Named Executive Officers' total
         annual salary and bonus.

</TABLE>

                                      - 1 -

<PAGE>




(2)      Ms. Shogen  resigned  from her position as the  Company's  President in
         August  1996 and Chief  Financial  Officer in July 1994.  No salary was
         paid to Ms.  Shogen in fiscal  1995 and 1994 and these  salary  amounts
         were accrued on the Company's financial  statements as obligations owed
         to Ms.  Shogen.  During  fiscal  1996,  Ms.  Shogen  was paid  $225,978
         representing  payment in full of accrued  back salary.  Ms.  Shogen was
         paid her  salary in full for  fiscal  1996.  In  consideration  for her
         services to the  Company  through  January  31,  1994 and Ms.  Shogen's
         agreement  to  release  the  Company  from  its  obligation  to pay her
         $1,624,151  in  accrued  salary on the  Company's  balance  sheet as of
         January 31, 1994, in March 1994 the Company  granted Ms. Shogen options
         to purchase 841,529 shares of the Company's Common Stock at an exercise
         price of $3.20 per share.

(3)      These options were originally granted during the fiscal year ended July
         31, 1992,  and were due to expire by their terms in September  1995. In
         September  1995,  the  exercise  period for these  options was extended
         until  September 1996 and the per share exercise price was increased to
         the  fair  market  value  of the  Common  Stock  on the  date  of  such
         extension.

(4)      No options were granted to the Named Executive Officers during the
         fiscal year ended July 31, 1995.

(5)      Ms. Fraser became an employee of the Company on July 15, 1994.  $96,163
         of Ms. Fraser's salary in fiscal 1995 was paid to Ms. Fraser.  That
         portion of Ms. Fraser's salary which was not paid to her was accrued on
         the Company's financial statements as obligations owed to Ms. Fraser.
         During fiscal 1996, Ms. Fraser was paid $25,000 representing payment in
         full of accrued back salary.  Ms. Fraser was paid her salary in full
         for fiscal 1996.

(6)      Prior to Ms. Fraser  joining the Company,  Ms. Fraser  received under a
         consulting  agreement an option to purchase 50,000 and 75,000 shares of
         the  Company's  Common  Stock at  exercise  prices of $3.22 and  $5.00,
         respectively.  On July 15,  1994,  Ms.  Fraser was  granted  options to
         purchase  350,000  shares of Common Stock under the Plan at an exercise
         price of $4.11 per share.

(7)      No salary was paid to Dr. Mikulski in fiscal 1994.  $5,000 of Dr.
         Mikulski's salary in fiscal 1995 was paid to Dr. Mikulski.  During
         fiscal 1996, Dr. Mikulski was paid $194,996 representing payment in
         full of accrued back salary.  Dr. Mikulski was paid his salary in full
         for fiscal 1996.  Those portions of Dr. Mikulski's salaries which were
         not paid to him were accrued on the Company's financial statements as
         obligations owed to Dr. Mikulski.  In consideration for his services to
         the Company and Dr. Mikulski's agreement to release the Company from
         its obligation to pay him $639,619 in accrued salary on the Company's
         balance sheet as of January 31, 1994, in March 1994 the Company granted
         Dr. Mikulski options to purchase 331,409 shares of the Company's Common
         Stock at an exercise price of $3.20 per share.


         The  Prospectus  is  further   supplemented   by  amending   "Executive
Compensation" to add the following table in its entirety:



                                      - 2 -

<PAGE>




                        OPTION GRANTS IN LAST FISCAL YEAR

         The following table contains information  concerning the grant of stock
options to the Named  Executive  Officers  during the fiscal year ended July 31,
1996.

<TABLE>
<CAPTION>

====================================================================================================================================
                                         Individual Grants

- ---------------------------------------------------------------------------------------------
                                                                                               Potential Realizable Value at Assumed
                                            % of Total Options     Exercise or                      Annual Rates of Stock Price
                            Options       Granted to Employees     Base Price     Expiration     Appreciation for Option Term (2)
         Name             Granted (#)          in Fiscal Year       ($/Share)        Date

                                                                                                     0%($)    5%($)          10%($)
- ----------------------------------------------------------------------------------------------------------------------------------- 

<S>                        <C>                       <C>            <C>             <C>              <C>     <C>            <C>     
Kuslima Shogen             500,000(1)                --              $3.87          9/16/96            0     $96,750        $193,500

Gail E. Fraser                 0                     --               --               --              -           -               -

Stanislaw M. Mikulski      250,000(1)                --               3.87          9/16/96            0     $48,375         $96,750
====================================================================================================================================

</TABLE>

(1)      These options were originally granted during the fiscal year ended July
         31, 1992 and were due to expire by their terms in  September  1995.  In
         September  1995, the exercise period for these options was extended and
         the per share  exercise price was increased to the fair market value of
         the Common Stock on the date of such extension.  The Board of Directors
         approved  extension  of  the  exercise  period  and  adjustment  of the
         exercise  price for these  options along with certain other options due
         to expire in 1995 as an inducement for the exercise of such options.

(2)      The amounts set forth in the three columns represent hypothetical gains
         that might be achieved by the optionees if the  respective  options are
         exercised at the end of their  terms.  These gains are based on assumed
         rates  of  stock  price   appreciation  of  0%,  5%  and  10%.  The  0%
         appreciation  column is  included  because  the  exercise  price of the
         options equals the market price of the  underlying  Common Stock on the
         date the  exercise  period of the options was  extended,  and thus will
         have no value  unless the  Company's  stock price  increases  above the
         exercise price.

                                      - 3 -

<PAGE>



         The  Prospectus  is  further   supplemented  by  amending  the  Selling
Stockholders'  Table to delete "Maronde,  John and Gretchen JT TEN" as a Selling
Stockholder, and include as a Selling Stockholder their transferee, as follows:

<TABLE>
<CAPTION>

                                                                     Number of
                                                                      Shares
                                                                      Offered
                                                       Number of        and           Number of                         Percentage
                                                        Shares       Acquired          Shares                               of
                                      Number of         Offered         in             Offered                          Outstanding
                                       Shares             and         October        Underlying        Number of       Shares to be
                                       Offered         Acquired        1994           Options,       Shares to be          Owned
                                         and              in            and           the Bank           Owned         Beneficially
                    Number of        Acquired in       September     September       Warrant and     Beneficially          After
                     Shares          March 1994          1994          1995          Issued Upon         After          Completion
Selling           Beneficially         Private          Private       Private         Exercise        Completion            of
Stockholders          Owned           Placement        Placement     Placement       of Options       of Offering         Offering
- ------------      ------------        ---------        ---------     ---------       ----------       -----------       ----------

<S>                   <C>                 <C>              <C>           <C>              <C>              <C>               <C> 
JAM Trust             67,100              40,000           0             0                0                27,100            *

</TABLE>


         All initially capitalized terms used herein shall have the same meaning
as specified in the Prospectus.


                 The date of this Supplement is October 31, 1996


                                      - 4 -



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission